Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 3/20 | 0.40 |
| ▸ | MAOB | P27338 | 3/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 2/20 | 0.30 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.30 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.30 |
| ▸ | APEX1 | P27695 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20158969 | 1.00 | MAOA (0.40) | MAOAMAOBATMSMN1; SMN2GRM2 | |
| SCHEMBL30148983 | 1.00 | MAOA (0.40) | MAOAMAOBATMSMN1; SMN2GRM2 | |
| SCHEMBL30168200 | 0.85 | MAOA (0.38) | MAOAMAOBATMSMN1; SMN2GRM2 | |
| SCHEMBL8895922 | 0.82 | ATM (0.53) | ATMGAA | |
| SCHEMBL25485065 | 0.82 | MAOA (0.40) | MAOAMAOBATMGRM2APEX1 | |
| SCHEMBL5067978 | 0.82 | ATM (0.53) | ATMGAA | |
| SCHEMBL21290883 | 0.82 | ATM (0.53) | ATMGAA | |
| SCHEMBL7267129 | 0.82 | OGA (0.38) | MAOAMAOBATMGAA | |
| SCHEMBL7267134 | 0.82 | OGA (0.38) | MAOAMAOBATMGAA | |
| SCHEMBL19293080 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180134690-A1 | INDAZOLES AND USE THEREOF | PURDUE PHARMA LP (US) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134690-A1 | INDAZOLES AND USE THEREOF | TRPV3, TRPA1, TRPV1 | MAOA 2268/4885MAOB 1323/4885ATM 3968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.